The test will be used to identify men with metastatic, castrate-resistant prostate cancer and germline BRCA mutations who are enrolled in a study for olaparib.
Maintenance treatment with Clovis' rucaparib may be a more tolerable maintenance therapy than chemo in platinum-responsive patients with mutations in BRCA1/2 or PALB2.
Investigators from the pharma concluded that most liquid biopsy false positives and negatives could be traced to technical specifics of individual tests.
Developed in collaboration with Waters and Labcyte, the platform enables applications including high-throughput drug screening and metabolomic profiling.
The BioFire FilmArray Pneumonia panel will be used to optimize clinical trial enrollment for an antibiotic to treat combat carbapenem-resistant A. baumannii infections.
The test is now approved as a CDx for advanced ovarian cancer patients considering Lynparza as a first-line maintenance treatment.
Plans are in place for a Guardant360-based assay to predict response to AsztraZeneca's Tagrisso and for a blood-based TMB test using the larger GuardantOmni panel.
The firms will begin a prospective lung cancer study using Biocartis' Idylla EGFR mutation test in European countries, including Belgium, France, Germany, and Italy.
In this arm of the trial, 23 percent of patients treated with AKT1 E17K mutations saw their tumors shrink, a better result than those seen in three other trial arms.
Bloomberg reports that the DNA-for-cash deal reported in Kentucky might be a more widespread scam.
St. Jude Children's Research Hospital scientists have treated infants with X-linked severe combined immunodeficiency using gene therapy in an early phase study.
St. Louis Public Radio reports that some African Americans are turning to DNA ancestry testing to help guide genealogical searches.
In Nature this week: a genomic analysis of the snailfish Pseudoliparis swirei, ancient DNA analysis gives insight into the introduction of farming to England, and more.